

Overactive Bladder Drug-China Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/O85D8E015F2MEN.html>

Date: March 2018

Pages: 155

Price: US\$ 2,980.00 (Single User License)

ID: O85D8E015F2MEN

Abstracts

Report Summary

Overactive Bladder Drug-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Overactive Bladder Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Overactive Bladder Drug 2013-2017, and development forecast 2018-2023

Main market players of Overactive Bladder Drug in China, with company and product introduction, position in the Overactive Bladder Drug market

Market status and development trend of Overactive Bladder Drug by types and applications

Cost and profit status of Overactive Bladder Drug, and marketing status

Market growth drivers and challenges

The report segments the China Overactive Bladder Drug market as:

China Overactive Bladder Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North China

Northeast China

East China

Central & South China

Southwest China

Northwest China

China Overactive Bladder Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Others

China Overactive Bladder Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

China Overactive Bladder Drug Market: Players Segment Analysis (Company and Product introduction, Overactive Bladder Drug Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma, Inc. (Japan)

Pfizer, Inc. (U.S.)

Teva Pharmaceutical Industries Limited (Israel)

Allergan, Plc (Ireland)

Medtronic plc (Ireland)

Mylan N.V. (U.S.)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Sanofi (France)

Apotex, Inc. (Canada)

Cogentix Medical, Inc. (U.S.)

Aurobindo Pharma Limited (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OVERACTIVE BLADDER DRUG

- 1.1 Definition of Overactive Bladder Drug in This Report
- 1.2 Commercial Types of Overactive Bladder Drug
 - 1.2.1 Anticholinergics
 - 1.2.2 Solifenacin
 - 1.2.3 Oxybutynin
 - 1.2.4 Darifenacin
 - 1.2.5 Fesoterodine
 - 1.2.6 Tolterodine
 - 1.2.7 Trospium
 - 1.2.8 Others
- 1.3 Downstream Application of Overactive Bladder Drug
 - 1.3.1 Idiopathic Bladder Overactivity
 - 1.3.2 Neurogenic Bladder Overactivity
- 1.4 Development History of Overactive Bladder Drug
- 1.5 Market Status and Trend of Overactive Bladder Drug 2013-2023
 - 1.5.1 China Overactive Bladder Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Overactive Bladder Drug Market Status and Trend 2013-2023

CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Overactive Bladder Drug in China 2013-2017
- 2.2 Consumption Market of Overactive Bladder Drug in China by Regions
 - 2.2.1 Consumption Volume of Overactive Bladder Drug in China by Regions
 - 2.2.2 Revenue of Overactive Bladder Drug in China by Regions
- 2.3 Market Analysis of Overactive Bladder Drug in China by Regions
 - 2.3.1 Market Analysis of Overactive Bladder Drug in North China 2013-2017
 - 2.3.2 Market Analysis of Overactive Bladder Drug in Northeast China 2013-2017
 - 2.3.3 Market Analysis of Overactive Bladder Drug in East China 2013-2017
 - 2.3.4 Market Analysis of Overactive Bladder Drug in Central & South China 2013-2017
 - 2.3.5 Market Analysis of Overactive Bladder Drug in Southwest China 2013-2017
 - 2.3.6 Market Analysis of Overactive Bladder Drug in Northwest China 2013-2017
- 2.4 Market Development Forecast of Overactive Bladder Drug in China 2018-2023
 - 2.4.1 Market Development Forecast of Overactive Bladder Drug in China 2018-2023
 - 2.4.2 Market Development Forecast of Overactive Bladder Drug by Regions 2018-2023

CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole China Market Status by Types

3.1.1 Consumption Volume of Overactive Bladder Drug in China by Types

3.1.2 Revenue of Overactive Bladder Drug in China by Types

3.2 China Market Status by Types in Major Countries

3.2.1 Market Status by Types in North China

3.2.2 Market Status by Types in Northeast China

3.2.3 Market Status by Types in East China

3.2.4 Market Status by Types in Central & South China

3.2.5 Market Status by Types in Southwest China

3.2.6 Market Status by Types in Northwest China

3.3 Market Forecast of Overactive Bladder Drug in China by Types

CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Overactive Bladder Drug in China by Downstream Industry

4.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Overactive Bladder Drug by Downstream Industry in North China

4.2.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in Northeast China

4.2.3 Demand Volume of Overactive Bladder Drug by Downstream Industry in East China

4.2.4 Demand Volume of Overactive Bladder Drug by Downstream Industry in Central & South China

4.2.5 Demand Volume of Overactive Bladder Drug by Downstream Industry in Southwest China

4.2.6 Demand Volume of Overactive Bladder Drug by Downstream Industry in Northwest China

4.3 Market Forecast of Overactive Bladder Drug in China by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OVERACTIVE BLADDER DRUG

5.1 China Economy Situation and Trend Overview

5.2 Overactive Bladder Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 OVERACTIVE BLADDER DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA

6.1 Sales Volume of Overactive Bladder Drug in China by Major Players

6.2 Revenue of Overactive Bladder Drug in China by Major Players

6.3 Basic Information of Overactive Bladder Drug by Major Players

6.3.1 Headquarters Location and Established Time of Overactive Bladder Drug Major Players

6.3.2 Employees and Revenue Level of Overactive Bladder Drug Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 OVERACTIVE BLADDER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma, Inc. (Japan)

7.1.1 Company profile

7.1.2 Representative Overactive Bladder Drug Product

7.1.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Astellas Pharma, Inc. (Japan)

7.2 Pfizer, Inc. (U.S.)

7.2.1 Company profile

7.2.2 Representative Overactive Bladder Drug Product

7.2.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Pfizer, Inc. (U.S.)

7.3 Teva Pharmaceutical Industries Limited (Israel)

7.3.1 Company profile

7.3.2 Representative Overactive Bladder Drug Product

7.3.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited (Israel)

7.4 Allergan, Plc (Ireland)

7.4.1 Company profile

7.4.2 Representative Overactive Bladder Drug Product

7.4.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Allergan, Plc (Ireland)

7.5 Medtronic plc (Ireland)

7.5.1 Company profile

7.5.2 Representative Overactive Bladder Drug Product

7.5.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Medtronic plc (Ireland)

7.6 Mylan N.V. (U.S.)

7.6.1 Company profile

7.6.2 Representative Overactive Bladder Drug Product

7.6.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Mylan N.V. (U.S.)

7.7 Endo International plc (Ireland)

7.7.1 Company profile

7.7.2 Representative Overactive Bladder Drug Product

7.7.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Endo International plc (Ireland)

7.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)

7.8.1 Company profile

7.8.2 Representative Overactive Bladder Drug Product

7.8.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Hisamitsu Pharmaceutical Co., Inc. (Japan)

7.9 Sanofi (France)

7.9.1 Company profile

7.9.2 Representative Overactive Bladder Drug Product

7.9.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Sanofi (France)

7.10 Apotex, Inc. (Canada)

7.10.1 Company profile

7.10.2 Representative Overactive Bladder Drug Product

7.10.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Apotex, Inc. (Canada)

7.11 Cogentix Medical, Inc. (U.S.)

7.11.1 Company profile

7.11.2 Representative Overactive Bladder Drug Product

7.11.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Cogentix Medical, Inc. (U.S.)

7.12 Aurobindo Pharma Limited (India)

7.12.1 Company profile

7.12.2 Representative Overactive Bladder Drug Product

7.12.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Aurobindo

Pharma Limited (India)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OVERACTIVE BLADDER DRUG

8.1 Industry Chain of Overactive Bladder Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OVERACTIVE BLADDER DRUG

9.1 Cost Structure Analysis of Overactive Bladder Drug

9.2 Raw Materials Cost Analysis of Overactive Bladder Drug

9.3 Labor Cost Analysis of Overactive Bladder Drug

9.4 Manufacturing Expenses Analysis of Overactive Bladder Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF OVERACTIVE BLADDER DRUG

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Overactive Bladder Drug-China Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/O85D8E015F2MEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O85D8E015F2MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970